Antibodies to cross-linked amyloid beta oligomers

Abstract

The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.

We claim: 
     
         1 .- 13 . (canceled) 
     
     
         14 . A method for treating or preventing Alzheimer's disease, comprising
 administering to a subject in need of such treatment an amount of antibodies, or antigen-binding fragments thereof, that bind to an oxidized form of amyloid β.   
     
     
         15 . The method of  claim 14 , wherein the oxidized form of amyloid β is cross-linked β-amyloid protein species (CLAPS). 
     
     
         16 . The method of  claim 14 , wherein the antibodies are made by administering an oxidized form of amyloid β to a mammal to produce antibodies that bind the oxidized form of amyloid β. 
     
     
         17 . The method of  claim 16 , wherein the oxidized form of amyloid β is cross-linked β-amyloid protein species (CLAPS). 
     
     
         18 . The method of  claim 17 , wherein the CLAPS are 15-35 kDa. 
     
     
         19 . The method of  claim 16 , wherein the mammal is a non-human species comprising human immunoglobulin genes. 
     
     
         20 . The method of  claim 19 , wherein the non-human species is a mouse. 
     
     
         21 . The method of  claim 14 , wherein the antibodies or fragments thereof are human antibodies or fragments thereof. 
     
     
         22 . The method of  claim 14 , wherein the antibodies or fragments thereof are humanized or chimeric antibodies, or fragments thereof. 
     
     
         23 . The method of  claim 14 , wherein the antibody fragments are selected from the group consisting of Fab fragments, F(ab′) 2  fragments, and Fv fragments. 
     
     
         24 . The method of  claim 14 , wherein the antibodies are single chain antibodies.